Last Updated : May 3, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort ascending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Inlyta (RFA) | Axitinib | Metastatic Renal Cell Carcinoma | N/A | Complete | ||
| Inlyta | Axitinib | Metastatic Renal Cell Carcinoma | Reimburse | Complete | ||
| Inflectra (Subsequent Entry Biologic) | Infliximab | Crohn’s disease and Ulcerative Colitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Inflectra | Infliximab | Ankylosing spondylitis; arthritis, psoriatic; arthritis, rheumatoid; plaque psoriasis | List with criteria/condition | Complete | ||
| Incruse Ellipta | Umeclidinium | Chronic obstructive pulmonary disease | List with criteria/condition | Complete | ||
| Increlex | mecasermin | Severe primary insulin-like growth factor-1 deficiency | Reimburse with clinical criteria and/or conditions | Complete | ||
| Incivek | Telaprevir | Hepatitis C, chronic | List with clinical criteria and/or conditions | Complete | ||
| Incivek | Telaprevir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
| Incivek | Telaprevir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
| Imvexxy | estradiol | Dyspareunia | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 3, 2024